NuVasive — Q3 2016 Earnings Presentation
14 slides from NuVasive's earnings presentation, Oct 25, 2016
Slide 1: Q3 2016 Results Supplemental Presentation to Earnings Press Release
Q3 2016 Results Supplemental Presentation to Earnings Press Release October 25, 2016 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements Q3 2016 RESULTS NuVasive cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove cor
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures Q3 2016 RESULTS Management uses certain non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating profit margin, which exclude amortization of intangible assets, non-cash purchase accounting ad
Slide 4: Third Quarter 2016 Performance
Third Quarter 2016 Performance* Q3 2016 RESULTS *Performance growth reflects comparison to prior year period; for additional details regarding full year 2016 guidance, see slide 13. ü Reported revenue growth of 19.5% to $239.6 million, or 18.9% on a constant currency basis. Delivered GAAP operating
Slide 5: NuVasive's Formula for Success
2 1 3 PROFITABILITY Operational excellence delivering significant margin expansion GROWTH Driving organic growth with numerous inorganic opportunities available INNOVATION Industry disruptor adding value and addressing unmet needs NuVasive’s Formula for Success Fueling 2016 strategic agenda with pro
Slide 6: Third Quarter 2016 Revenue Highlights
Third Quarter 2016 Revenue Highlights Q3 2016 RESULTS 14.6% U.S. SPINAL HARDWARE Includes All Implants, Fixation, MAGEC® & PRECICE® 25.6% 23.0%* *Constant currency basis U.S. SURGICAL SUPPORT Includes Biologics, IOM Services & Disposables INTERNATIONAL Includes Puerto Rico Key Performance Factors Co
Slide 7: Third Quarter 2016 P&L Performance
Q3 2016 RESULTS Third Quarter 2016 P&L Performance Operating leverage story continues to play out NON-GAP MEASURES 3Q16 ACTUALS 3Q16 YOY PEFORMANCE FACTORS Gross Margin Sales, Marketing + Admin Research + Development Operating Profit Margin EPS Adjusted EBITDA Margin 76.3% 55.0% 5.2% 16.1% $0.40 25.
Slide 8: Driving ~20% CAGR in Adjusted EBITDA Improvements
Q3 2016 RESULTS Driving ~20% CAGR in Adjusted EBITDA Improvements *NuVasive financial performance guidance as of October 25, 2016; reflects Adjusted EBITDA margin for full year 2016 of 25.4% Incremental focus on improving the working capital profile and CapEx spending will drive incremental gains in
Slide 9: Driving Improved Non-GAAP Operating Profit Margin
Q3 2016 RESULTS Driving Improved Non-GAAP Operating Profit Margin *NuVasive financial performance guidance as of October 25, 2016; includes an impact of ~70 bps from NSO ~16% 15.4% 11.4% 9.2% Driving improved profitability through disciplined spending and improved efficiencies while adding acquisiti
Slide 10: Driving Improved Tax Rate
Q3 2016 RESULTS Driving Improved Tax Rate Focused on reducing tax rate through international scale and domestic tax planning *NuVasive financial performance guidance as of October 25, 2016. Opportunity to drive non-GAAP effective tax rate lower by ~1,400 bps over 5 years. OPERATING IMPROVEMENTS TAKI
Slide 11: 2016 NASS: iGA Platform for Cervical
2016 NORTH AMERICAN SPINE SOCIETY (NASS) iGA Platform for Cervical Furthers computer-aided surgical planning and workflow to drive consistent, verified outcomes Includes the launch of Bendini® OCT, which is able to bend spinal rods for occipito-cervico-thoracic (OTC) cases First expanded platform th
Slide 12: 2016 NASS: Low-Radiation Imaging Software
2016 NORTH AMERICAN SPINE SOCIETY (NASS) Software that enables O.R. staff to reduce their levels of exposure to surgical radiation Will help increase adoption of minimally invasive surgery without any disruption of surgeon’s familiar workflow Takes low radiation images and improves them to look like
Slide 13: Full Year 2016 Financial Performance Guidance
Q3 2016 RESULTS Full Year 2016 Financial Performance Guidance* *NuVasive financial performance guidance as of October 25, 2016; ^Constant currency FY16 Guidance Performance Drivers Revenues As reported ~$952.0M, ~17.2% YoY growth^ ~$53M NSO contribution, ~$27M Biotronic; ~$1M currency impact U.S. Sp
Slide 14: Why Invest in NuVasive?
Q3 2016 RESULTS Why Invest in NuVasive? Relentless focus on driving shareholder value *NuVasive financial performance guidance as of October 25, 2016 Industry-leading innovation and integrated procedural solutions enables share-taking and premium pricing Drive surgeon conversion, increase service li